Skip to main content
SpringerLink
Log in

Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

ImuVert, a new biological response modifier of bacterial origin, was evaluated in a Phase II trial of patients with metastatic prostate cancer. Sixteen patients with hormone refractory measurable or evaluable disease were treated with ImuVert 1.0 mg subcutaneously once weekly for 5 weeks. After a 1 week rest period, the dose was escalated to 3.0 mg weekly for 5 additional weeks. Eleven patients received the full 10 weeks of therapy. Toxicity consisted of mild transient flu-like symptoms as well as the development of tenderness and induration at injection sites. No patient responded to treatment. ImuVert at this dose and schedule is inactive in advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mittleman A, Urban R, Ahmed T, Arnold P, Chiao J, Arlin Z: The effect of ImuVert on OKT4, OKT8, and natural killer cells in patients with advanced malignancies. Clin Res 34:493A, 1986

    Google Scholar 

  2. Ascensao J, Mittleman A, Penichet KO, Lin BY, Urban R, Feldman E, Arlin Z, Podack ER: Activated natural killer cell activity in patients with advanced cancer treated with ImuVert. (Abstr) Proc Am Assoc Cancer Res 28:1457, 1987

    Google Scholar 

  3. Mittleman A, Urban R, Feldman E, Ahmed T, Zelkowitz R, Friedland M, Arnold P, Glover P, Arlin Z: A bacterial cell component as a new biologic response modifier: A Phase I study. (Abstr) Proc Am Assoc Cancer Res 27:1238, 1986

    Google Scholar 

  4. Feldman E, Mittleman A, Urban R, Glover P, Arnold P, Kruger G, Ahmed T, Arlin Z: A Phase I trial of a natural membrane vesicle containing ribosomes (ImuVert) in patients with advanced cancer (an alternate schedule). (Abstr) Proc Am Assoc Cancer Res 9:931, 1987

    Google Scholar 

  5. Schmidt JD, Johnson DE, Scott WW, Gibbons RP, Prout GR, Murphy GP: Chemotherapy of advanced prostatic cancer: evaluation of response parameters. Urology 7:602–610, 1976

    Google Scholar 

  6. Jaeckle KA, Mittleman A, Feldman E, Savona S, Word J, Urban R: Phase II trial of ImuVert in recurrent malignant astrocytomas. (Abstr) Proc Am Soc Clin Oncol, in press, 1988

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Oncology, University of Texas Health Science Center, 78284, San Antonio, TX, USA

    C. Kent Osborne, John B. Craig & Judith Turner

  2. Department of Surgery, Division of Urology, University of Colorado Health Science Center, 80262, Denver, CO, USA

    Kathy Klein & E.David Crawford

Authors
  1. C. Kent Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John B. Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathy Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E.David Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Judith Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osborne, C.K., Craig, J.B., Klein, K. et al. Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Invest New Drugs 7, 243–245 (1989). https://doi.org/10.1007/BF00170867

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00170867

Key words

Search

Navigation